KalVista PharmaceuticalsKALV
KALV
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
72% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 29
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
7% more funds holding
Funds holding: 122 [Q3] → 130 (+8) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
0.34% less ownership
Funds ownership: 112.01% [Q3] → 111.68% (-0.34%) [Q4]
17% less capital invested
Capital invested by funds: $561M [Q3] → $467M (-$93.5M) [Q4]
94% less call options, than puts
Call options by funds: $115K | Put options by funds: $1.8M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
53%
upside
Avg. target
$23
86%
upside
High target
$30
141%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger 40% 1-year accuracy 49 / 123 met price target | 125%upside $28 | Buy Reiterated | 8 Apr 2025 |
Citizens Capital Markets Jonathan Wolleben 34% 1-year accuracy 23 / 67 met price target | 53%upside $19 | Market Outperform Reiterated | 26 Mar 2025 |
Jones Trading Debanjana Chatterjee 17% 1-year accuracy 1 / 6 met price target | 141%upside $30 | Buy Maintained | 26 Mar 2025 |
HC Wainwright & Co. Andrew Fein 26% 1-year accuracy 93 / 355 met price target | 61%upside $20 | Buy Reiterated | 14 Mar 2025 |
JMP Securities Jonathan Wolleben 34% 1-year accuracy 23 / 67 met price target | 53%upside $19 | Market Outperform Initiated | 31 Jan 2025 |
Financial journalist opinion
Based on 5 articles about KALV published over the past 30 days
Positive
Seeking Alpha
1 week ago
KalVista: Poised For Rare Disease Transformation
KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial position with $253.2 million in cash, bolstered by $160 million in recent financing, ensures readiness for commercialization. Strategic partnerships, including a licensing deal with Kaken Pharmaceutical in Japan, and successful pediatric trial progress, de-risk and expand market potential.
Neutral
Business Wire
2 weeks ago
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement o.
Neutral
Business Wire
3 weeks ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 87,000 shares of KalVista common stock on April 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on.
Neutral
Business Wire
3 weeks ago
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals,.
Neutral
Business Wire
4 weeks ago
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE). “We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial siz.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update. "Sebetralstat is poised to be the first and only oral on-demand treatment for HAE, with the potential to become the foundational treatment for this disease," said Ben Palleiko, Chief Executive Officer of KalVista. "With seven regulatory submissions globally and the first re.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company's investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here. In addition to presentations by KalVista's management team,.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on March 3, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. “The growing body of data from the KONFIDENT-S study consistently demo.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:10 p.m. ET in Boston, MA Leerink Partners 2025 Global Healthcare Conference on Monday, March 10, 2025, at 8:00 a.m. ET in Miami, FL Each presentation will be live webcast on the Company's website at www.k.
Charts implemented using Lightweight Charts™